The frequencies of TRACCAR T cells detected at the CD22(+) tumor sites were similar in all groups regardless of IL-12P70 status (Fig. 5b, left graph), suggesting that genetic engineering does not affect the trafficking or early accumulation of T cells. Here, CD22 is linked to neoplasm.